1. Trans-Atlantic Cooperation Technology Transfer Office Director Johan C. Haveland Washington DC 03.12.04

2. University of Bergen 7 faculties +17 000 students 2 800 faculty and staff urban high quality research international collaborations

3. Profile research education communication marine environment international co-operation

4. Track Record and projects 2 spin-outs sold for $20M+ each 2 running spinouts with more than $7M annual revenue 18 running spinouts New patents –Methane Hydrate (US based oil company) –Platform technology for bio- nano (tunnelling nano tubes) –MR-imaging algorithm for rapid pictures from MRi- scanners Hans-Herrmann Gerdes et. Al. – TNTs published in Science 13.02.04

5. Establishing US biotech comp. in Bergen Currently developing collaboration model with a San Francisco biotech company –using IPR owned by biotech –using unique UiB expertise and positioning towards translational medicine –building Norwegian role in international market –capitalising on biotech’s existing sales network Goal: new joint-owned company in Norway Agreed Goal – –Q2 2005: proof of concept; –Q3 2005: start-up.

6. UniTargetingResearch Protein drugs: a $33 bn industry (growth 30%) –Large product pipeline –Considerably undersized production capacity UTR® technology: up to 30-fold production yields. –Genetically engineered vectors for mammalian cell production –Boosts secretion of proteins Also intracellular & membrane proteins: purify from medium, not cells! –Customers: biopharma, contract manufacturers, small biotech Validated for antibody production and gene therapy. Management and advisors from Serono, Eli Lilly, leading academia. Raising €1-3 mln.

7. Novel Diagnostics Test kit for early detection of colorectal cancer –Emerging screening market Europe $6 billion –Norway: 3000 kits sold –Rollout plan for Europe Acute phase detection of infectious disease –Significantly improves $1,9 bn ELISA platform –HIV: ongoing clinical trials South Africa –Tuberculosis: ongoing clinical trials by bioMerieux. Management, executives from Abbott Labs, Johnson & Johnson, Murex Diagnostics, Wellcome Diagnostics (Now GlaxoSmithKline) Raising €3-10 mln, €3 placed NAT Amount HIV infected 20 EIA 10 PlasmAcute®

8. MediMush Biopharmaceuticals and nutraceuticals from medicinal mushrooms, high end market: $2-3 bn MediMush production (patented) –Ingredients of superior quality, purity, and at a fraction of current costs Key issues to supplement, nutraceuticals suppliers Enables oral medicine delivery, Sine Parmaceautical Company (China) #1 Product (Lentinan), under validation by General Nutrition Company (USA) –Animal testing with US National Cancer Institute and University of Louisiana. Management from nutraceuticals business, academia. Raising €1-3 million Lentinan for injection Shitake

9. Sarsia Innovation Seed Capital Meltzer Foundation Unifob Foundation Phases of commercialisation Ideas Project Develop. Seed Capital Sales/IPO Regional TTO Inc from 22.12.04 Service providers/ researchers UiB, University Hospital, Institte of Marine Research,Bergen University College, CMR, NIFES ForInnva InnoVest Incubator Start UpInvestment in growth Venture Capital Services Material Transfer Agreement Industrial cooperation IPR Management (external financing) Idea - advising Commercialisation - Resources Project evaluation/Market identification Scientific and Market Verification Unique technology (patent search and filing) Licensing vs start-up models… Proof of Concept: Prototype Preseed funding Selection of ideas for commercialization

10. Main Challenges for Regional TTO Ideas Project Develop. Seed Capital Venture Capital Sales/IPO Pre-Seed funding Seed Capital Venture- kapital Early selection citerias Market Evaluation Fewer companies Companies ready for VC Develop internal skills Attract capital

11. Trans-Atlantic Help TTO - Network for early stage selection of ideas Understanding of VC US Network for licencing